A Comparison of Serum and Urine N-telopeptide Marker

NeuroTherapia, Inc. logo

NeuroTherapia, Inc.


Active, not recruiting


Fractures, Bone


Diagnostic Test: N-Telopeptide, Bone Marker

Study type


Funder types




Details and patient eligibility


This is a prospective specimen collection cohort study to evaluate the correlation between serum and urine values of the bone marker of interest, and their association with baseline DEXA scan measures and fracture risk within 6 months. Study samples will be obtained longitudinally. One collection of both serum and urine collection will be obtained. The urine will be collected as second void of day and at the same time the blood collection is drawn. Study will continue for a period or 1 year, with plan to enroll around 40 subjects.

Full description

Osteoporosis is the most common metabolic disorder in the United States and it is estimated that approximately 19% of women and 4% of men over the age 50 years have underlying disease. This number is expected to continue to rise. A silent illness at first, once presenting with fractures, it can lead to increased morbidity, mortality, and decreased quality of life. It carries large financial and societal burdens. Direct annual medical costs are estimated to be approximately 17 to 20 billion dollars in the United States alone. Therefore, it is important to accurately identify those at high risk. The present gold standard to diagnose osteoporosis is the Dual-energy X-ray absorptiometry (DEXA scan) with a diagnosis based on a T-score of -2.5 SD or below in those without history of fragility fracture. However, many individuals fracture despite having normal or only mildly reduced scores. There are also several barriers within the DEXA technology including accessibility, cost, accurate reference ranges for age and demographic groups that result in missing large groups of people at risk for osteoporosis. The Fracture Risk Assessment Tool (FRAX score) is one tool that identifies those at higher risk of fracture that may benefit from therapy. It was designed and released in 2008 and has been a great asset in clinical practice in stratifying risk and guiding management of osteopenic patients. However, FRAX may miss many individuals that may benefit from therapy due to its limited inclusion criteria. Bone markers have been shown to predict fracture risk in postmenopausal women independent of bone mineral density and may help identify high risk individuals. Amino-terminal cross-linking telopeptides of type I collagen (NTX) reflects osteoclastic bone resorption. NTX can be measured in both the serum and in urine. The accuracy of the serum NTX is unclear. It may be less sensitive than urine NTX in detecting bone density changes. The urine NTX overcomes circadian rhythm changes to bone density and is less sensitive to dietary collagen intake. At present, urine markers need to be checked as a second void of the day which may be cumbersome for patients. Serum levels drawn with other bone labs would be easier to obtain than second void urine collections. The study team involved with this research would like to evaluate the correlation between serum and urine NTX in patients with osteopenia with no prior history of osteoporotic treatment. If the urine and serum markers are equivalent methods, serum levels would be preferred to identify high risk patients at risk of disease due to ease of collection.


40 patients




18 to 85 years old


No Healthy Volunteers

Inclusion criteria

  • Consent to participate in the study
  • Participants limited to subjects in the CCF
  • Age between and inclusive of 18 and 85 years of age
  • No gender exclusion
  • Patients diagnosed with Osteopenia on DEXA scan who have not been on any medical therapy in the past
  • Presence of normal vitamin D levels, kidney function, and parathyroid hormone levels (per our reference ranges)

Exclusion criteria

  • Prior history of medical therapy for osteopenia
  • Prior radiation therapy
  • Prior history of bone fracture
  • History of high risk medication associated with increased risk of fracture
  • Presence of abnormal vitamin D levels, kidney function, and parathyroid hormone
  • Pregnancy status (verbal)
  • Those with medical co-morbidities that increase the risk of fracture will be excluded and these include but are not limited to: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, diabetes mellitus, hyperparathyroidism, chronic kidney disease, pituitary disease, multiple myeloma, leukemia, lymphoma, thalassemia major, HIV/AIDS, malabsorption, Inflammatory bowel disease, chronic obstructive pulmonary disease, hypogonadism, chronic liver disease, untreated hyperthyroidism, and those with chronic immobility

Trial design

40 participants in 1 patient group

Osteopenia, no past medical therapy
Patients diagnosed with osteopenia on DEXA scan who have not been on any medical therapy in the past
Diagnostic Test: N-Telopeptide, Bone Marker

Trial contacts and locations



Central trial contact

Lea El Hage, MD; Kimberly Jenkins, MS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems